News
RDY
15.18
+0.46%
0.07
Weekly Report: what happened at RDY last week (1104-1108)?
Weekly Report · 7h ago
Biotech Alert: Searches spiking for these stocks today
TipRanks · 4d ago
Dr. Reddy’s to Engage with Investors in Mumbai
TipRanks · 4d ago
Dr. Reddy's reports Q2 results
Seeking Alpha · 5d ago
Dr Reddy's Labs Is Maintained at Overweight by Barclays
Dow Jones · 5d ago
Dr. Reddy’s Labs Releases Unaudited Financial Results
TipRanks · 5d ago
Dr Reddy’s Laboratories (RDY) Gets a Buy from Barclays
TipRanks · 5d ago
Dr. Reddy’s Reports Strong Q2FY25 Results and Strategic Expansions
TipRanks · 5d ago
Dr Reddy’s Financials Verified; Investor Confidence Boosted
TipRanks · 5d ago
Dr. Reddy’s Laboratories Reports Q2 Revenue Growth
TipRanks · 5d ago
Dr. Reddy's Lab Delivers 'Another Good Quarter,' CEO Says As Revenue Jumps 17%
Benzinga · 6d ago
UPDATE 1-India's Dr Reddy's misses Q2 profit view on weak pricing in North America
Reuters · 6d ago
UPDATE 2-India's Dr Reddy's Q2 profit drops on acquisition cost, impairment charge
Reuters · 6d ago
Dr Reddy's Laboratories Q2 2025 GAAP EPS $0.18 Compared To $0.21 YoY, Sales $957.00M Compared To $821M YoY
Benzinga · 6d ago
India's Dr Reddy's misses Q2 profit view on weak US demand
Reuters · 6d ago
Dr. Reddy’s Q2 & H1FY25 Financial Results
Barchart · 6d ago
Journey gets FDA okay for Emrosi, releases preliminary Q3 earnings
Seeking Alpha · 6d ago
Here's the major earnings before the open tomorrow
Seeking Alpha · 6d ago
Dr. Reddy’s Announces New Employee Stock Options
TipRanks · 6d ago
More
Webull provides a variety of real-time RDY stock news. You can receive the latest news about Dr Reddys Labs through multiple platforms. This information may help you make smarter investment decisions.
About RDY
Dr. Reddy’s Laboratories Limited is an India-based pharmaceutical company. Its products and services are spread across its core businesses of active pharmaceutical ingredients (APIs), generics, branded generics, biosimilars and over-the-counter (OTC) pharmaceutical products. It works in the areas of gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Its segments consist of Global Generics; Pharmaceutical Services and Active Ingredients (PSAI), and Others. The Global Generics segment consists of the Company's business of manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics). The Pharmaceutical Services and Active Ingredients segment consists of the Company's business of manufacturing and marketing APIs and intermediates.